UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 54,721 Shares of Amgen Inc. $AMGN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.2% in the fourth quarter, Holdings Channel.com reports. The fund owned 4,604,019 shares of the medical research company’s stock after buying an additional 54,721 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Amgen were worth $1,506,941,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. High Note Wealth LLC increased its holdings in shares of Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. increased its holdings in shares of Amgen by 0.7% in the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC increased its holdings in shares of Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares during the period. West Family Investments Inc. increased its holdings in shares of Amgen by 1.1% in the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the period. Finally, Viawealth LLC increased its holdings in shares of Amgen by 0.4% in the 3rd quarter. Viawealth LLC now owns 7,168 shares of the medical research company’s stock valued at $2,023,000 after acquiring an additional 30 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on AMGN shares. Jefferies Financial Group started coverage on Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target on the stock. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Daiwa Securities Group dropped their target price on Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 13th. Canaccord Genuity Group initiated coverage on Amgen in a research note on Monday, April 20th. They set a “hold” rating and a $366.00 target price on the stock. Finally, Morgan Stanley boosted their target price on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $354.12.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Amgen Stock Performance

Shares of AMGN stock opened at $355.20 on Friday. The stock has a market cap of $191.70 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 3.55 and a beta of 0.42. The business has a 50-day simple moving average of $340.97 and a 200-day simple moving average of $345.72. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 52-week low of $267.83 and a 52-week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.38 EPS for the current year.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.